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Exploiting nanobodies and Affimers for 
superresolution imaging in light microscopy
ABSTRACT Antibodies have long been the main approach used for localizing proteins of in-
terest by light microscopy. In the past 5 yr or so, and with the advent of superresolution mi-
croscopy, the diversity of tools for imaging has rapidly expanded. One main area of expan-
sion has been in the area of nanobodies, small single-chain antibodies from camelids or 
sharks. The other has been the use of artificial scaffold proteins, including Affimers. The small 
size of nanobodies and Affimers compared with the traditional antibody provides several 
advantages for superresolution imaging.
BACKGROUND
For many years, the scientific community has been using antibodies 
for localizing proteins of interest by immunofluorescence micros-
copy. This approach is well established and works well for standard 
wide-field and confocal fluorescence imaging. However, more re-
cently, many researchers have begun to use “superresolution” im-
aging in their research to locate their proteins of interest with better 
resolution and precision. There are three main approaches to super-
resolution microscopy: structured illumination microscopy, which 
provides a twofold improvement in resolution compared with wide-
field; stimulated emission depletion (STED), which improves resolu-
tion by approximately fivefold (to ∼50 nm); and single-molecule 
localization microscopy (SMLM) approaches that include photoacti-
vatable light microscopy, stochastic optical reconstruction micros-
copy (STORM), and DNA points accumulation for imaging in na-
noscale topography (PAINT), which provide resolutions of ∼20 nm or 
better (recently reviewed in Schermelleh et al., 2019). As the resolu-
tion increases to ∼20 nm or better, the use of both primary and 
secondary antibodies starts to become limiting, particularly in 
SMLM approaches, and new labeling approaches are needed. This 
Perspective provides a short overview of the different approaches 
that have begun to be employed to overcome this limitation.
THE TRADITIONAL DUAL-ANTIBODY APPROACH 
INTRODUCES LOCALIZATION ERROR IN SMLM 
SUPERRESOLUTION IMAGING
The typical approach of labeling proteins in cells, which uses a com-
bination of primary and secondary antibodies, adds to the localiza-
tion error in SMLM approaches. Antibodies from most species con-
tain both heavy and light chains and are large in size (molecular 
mass of ∼150 kDa and ∼12 nm in length; Figure 1A). They can be 
polyclonal or monoclonal and tend to be immunoglobulin type G 
(IgG). In immunofluorescence applications, the location of the pri-
mary antibody is visualized using a fluorescently labeled secondary 
antibody that recognizes IgG from the species in which the primary 
antibody was raised. Secondary antibodies are almost always poly-
clonal and bind to various epitopes on the primary antibody. The 
secondary antibody is typically labeled with multiple dyes, usually 
by ε-amine labeling (e.g., via N-hydroxysuccinimydyl esters; Haug-
land, 1995), which attaches fluorophores to the lysine residues, of 
which there are many.
In wide-field or confocal imaging, with a resolution of ∼250 nm, 
the small uncertainty (∼20 nm) introduced by using a combination of 
primary and secondary antibodies is not significant or detectable. 
However, as the resolution of the imaging methods increases to-
ward that of SMLM, which has a resolution of 20 nm or better, anti-
body size combined with the polyclonal nature and multiple dye 
labels of the secondary antibody introduces an additional error in 
the localization precision for the target protein. Effectively, in SMLM, 
the location of the protein of interest is determined by imaging sev-
eral dye labels at some variable but considerable distance (∼20 nm) 
away from the protein of interest, which leads to a degree of uncer-
tainty about its actual position, the so-called linkage error.
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There are various strategies to overcome this problem. If a com-
bination of primary and secondary antibodies has to be used, then 
the secondary antibody can be labeled in such a way as to make 
sure it only has one dye label per antibody. This can be achieved by 
labeling the lysines via ε-amine labeling, and carefully monitoring 
the extent of the labeling. Alternatively, commercial kits are avail-
able to selectively reduce the disulfide bonds in the hinge region of 
the antibody and couple labels to the resulting free sulfhydryl 
groups, or to couple dyes to the polysaccharide groups, if present. 
All of these need care to make sure the antibody only contains one 
dye per molecule and that its properties are otherwise unaffected. 
Moreover, this approach does not overcome the polyclonal nature 
of the secondary antibody and still places the dye molecule at some 
uncertain distance away from the target protein.
Alternatively, the primary antibody can directly labeled. How-
ever, this can expensive, as it usually requires a minimum amount of 
source antibody to be labeled, and the dye:molecule ratio still 
needs to be controlled. The unspecific nature of ε-amine labeling 
can make this difficult to achieve and, in some cases, can eliminate 
the binding efficacy of the antibody by labeling on/or close to the 
antigen-binding site (Vira et al., 2010; Szabo et al., 2018). Even 
when successful, the fluorophore can still be ∼10 nm away from the 
epitope of interest. Using smaller Fab fragments that have been di-
rectly labeled will place the fluorophore closer to the protein of in-
terest, but Fab fragments are often not available commercially and 
normally have to be made in house. Clearly, alternatives to tradi-
tional antibody labeling are needed for SMLM-based superresolu-
tion imaging.
NANOBODIES: ALTERNATIVES TO THE TRADITIONAL 
DUAL ANTIBODY LABELING APPROACH IN SMLM 
SUPERRESOLUTION IMAGING
One solution to this problem is to use nanobodies. About 50% of 
the antibodies found in camelid species (Bactrian camels, alpacas, 
dromedaries, and llamas) are composed of a dimer of heavy chains 
only (isotypes IgG2 and IgG3). The size of these heavy chains is 
considerably smaller than those of mammalian antibodies (Hamers-
Casterman et al., 1993), and the single N-terminal domain of these 
antibodies does not need to pair with a second heavy chain in order 
to bind specifically to its protein target. Similarly, some cartilaginous 
fish contain a subset of heavy-chain antibodies (Greenberg et al., 
1995) that are also able to function via a single monomeric variable 
antibody domain. These antibodies (or nanobodies) are thus much 
smaller (∼10–15 kDa) than the traditional monoclonal antibody 
(Figure 1A). It has become relatively routine to isolate the mRNA 
from blood lymphocytes from an immunized animal, subclone the 
VHH sequences into a phage display vector, and then generate 
small immune libraries (∼106 variants) for screening (Muyldermans, 
2001, 2013). Naïve (using nonimmunized animals) and synthetic/
semisynthetic libraries have also since been developed (for a review 
of recent technologies, see Liu et al., 2018), as have humanized 
nanobodies (Moutel et al., 2016).
The first elegant demonstration that nanobodies are useful for 
SMLM-based superresolution imaging, was shown through the use 
of the anti–green fluorescent protein (GFP) nanobody (Ries et al., 
2012), for example, to visualize GFP-tagged tubulin in microtubules. 
A second nanobody against red fluorescent protein has been used 
FIGURE 1: Size comparison between an antibody, a nanobody, and an Affimer. (A) An antibody, a nanobody, and an 
Affimer (to scale) are shown next to a microtubule. The antibody (IgG: 1RJH) is composed of heavy chains (blue) and 
light chains (gray). The nanobody (30G0) is composed of a single heavy chain (blue; see text), and the Affimer (4N6T) is 
also composed of a single polypeptide chain (blue). The location of a dye molecule attached to a C-terminal cysteine 
residue is indicated by the red star for the Affimer and the nanobody. Otherwise, dye molecules for the antibody and 
nanobody would be attached to one or more of the lysine residues (shown in cyan). (B) The structure of the Affimer in 
detail, showing the positions of the two variable loops that interact with its binding partner. The position of the 
C-terminus, where the dye molecule is attached to a unique cysteine residue, is indicated by the red star.
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similarly (Platonova et al., 2015), and nanobodies that recognize epi-
tope tags (Virant et al., 2018) have since been developed. However, 
to use these antibodies, the protein of interest must be tagged, 
which can affect its function and/or location. Nanobodies that rec-
ognize mouse or rat primary antibodies and that can be used as 
secondary antibodies have also been described (Pleiner et al., 2018).
Nanobodies have also been generated to a variety of proteins, 
including tubulin (Mikhaylova et al., 2015), to allow direct rather than 
indirect labeling of microtubules and have been used successfully in 
SMLM approaches, including DNA PAINT (Fabricius et al., 2018; 
Sograte-Idrissi et al., 2019). They have also been used successfully 
in correlative light and electron microscopy (EM) approaches (Fang 
et al., 2018) with better penetration than traditional antibodies. This 
approach (termed “NATIVE” for nanobody-assisted tissue immu-
nostaining for volumetric EM) is enabled by the better penetration 
of nanobodies into thick (500-µM) sections, without the need for 
permeabilization by detergents, which destroys lipid membranes.
As with traditional antibodies, nanobodies can be labeled via the 
ε-amine (lysine residues), and careful labeling can result in 1–1.5 la-
bels on average per nanobody (Platonova et al., 2015). However, a 
further innovation demonstrated that nanobodies could be gener-
ated with single cysteines for direct labeling at a single site (Pleiner 
et al., 2015). This approach demonstrated that the nanobodies 
could be relatively stable without the disulfide bonds they normally 
contain and could then be purified with high yields from the cyto-
plasm of Escherichia coli, rather than the periplasm (inclusion bod-
ies), as is more typical (Pleiner et al., 2015).
Importantly, in SMLM-based superresolution imaging, the small 
size of the nanobody combined with a single unique site for attach-
ing the dye label means that the fluorescent label is now placed 
∼2–4 nm away from the protein target, which provides better local-
ization precision.
“NON-ANTIBODY” APPROACHES TO LABELING 
PROTEINS IN SMLM SUPERRESOLUTION
A number of small molecules and peptides such as phalloidin (Xu 
et al., 2012) and LifeAct (Kiuchi et al., 2015) to label actin, Taxol 
derivatives to label tubulin (Lukinavicius et al., 2018), DNA interca-
lating dyes (Flors et al., 2009), and labels for endoplasmic reticulum 
and other organelles (Shim et al., 2012) have been used in SMLM-
based superresolution microscopy. These place the dye molecule 
very close to the protein of interest. However, these binders cannot 
be generated in a systematic way against a range of different target 
proteins. Moreover, in some instances, they do not appear to 
work well, an example being the use of phalloidin in DNA-PAINT 
(Schlichthaerle et al., 2018).
Many different alternatives to antibodies are now being devel-
oped that can bind to and label proteins. Typically, these consist of 
a protein scaffold into which variable binding loops or domains have 
been engineered to generate a combinatorial phagemid library that 
can be screened for binding to the protein target of interest (Nygren 
and Skerra, 2004; Skrlec et al., 2015). These binders can then be 
expressed and purified from E. coli. One of these is the Affibody 
(Lofblom et al., 2010), which is derived from the IgG-binding protein 
A from Staphylococcus and consists of a three-helix bundle (58 
amino acids in total). Another is the DARPin (designed ankyrin re-
peat proteins; Boersma and Pluckthun, 2011). In addition to protein-
based alternatives, aptamers (single-stranded DNA or RNA oligo-
nucleotides) have also been reported as useful in SMLM-based 
superresolution imaging (Opazo et al., 2012). However, so far, many 
of these antibody alternatives have not been well explored for their 
potential use in superresolution imaging.
Affimers are an example of another type of non-antibody bind-
ing alternative that has been used successfully in SMLM by our 
group and others (Tiede et al., 2017; Schlichthaerle et al., 2018). 
Affimers (Figure 1), originally named Adhirons (Tiede et al., 2014), 
are made up of a scaffold based on the plant phytocystatin protein. 
The Affimer contains two variable loops containing randomized 
amino acid sequences, and the combinatorial phagemid library 
comprises 1.3 × 1010 clones. The sequence is ∼100 amino acids long 
(10–12 kDa and ∼3 nm in size). The amino acid residue cysteine is 
excluded, which allows this residue to be cloned in at a later stage 
to either the N- or C-terminus to allow site-specific labeling. The 
protein itself is highly thermally stable, making purification of the 
Affimer (via an introduced His tag) from E. coli very simple, as most 
of the bacterial proteins can be denatured and precipitated by a 
short heat treatment before purification. The binding affinity of the 
Affimers is typically in the nanomolar range, and highly specific re-
agents can be isolated from the library (Tiede et al., 2014; Hughes 
et al., 2017; Tang et al., 2017; Robinson et al., 2018). As the Affimers 
are completely synthetic, they can also be screened against poten-
tially toxic polypeptides.
We reasoned that their small size and the ability to specifically 
add a fluorescent label via the unique cysteine residue would make 
Affimers ideal for superresolution imaging. We initially isolated four 
Affimers to rabbit skeletal F-actin (Lopata et al., 2018) and charac-
terized their ability to image F-actin in live and fixed cells using a 
variety of approaches. We followed this up by demonstrating that 
one of these Affimers (Affimer 14) performed well in both the 3D 
dSTORM and DNA PAINT approaches (Schlichthaerle et al., 2018), 
outperforming phalloidin. Similarly, we have raised an Affimer to 
tubulin that also works well in dSTORM (Tiede et al., 2017).
Affimers, like nanobodies, also have the advantage that their 
smaller size enables them to better penetrate regions of cells from 
which traditional antibodies are normally excluded. For example, 
the tubulin Affimer stained up the cytokinetic furrow, a region 
densely packed with microtubules, which does not stain up with the 
traditional antibody approach (Tiede et al., 2017). Similarly, nano-
bodies to SNAP-25 and Syntaxin A1 revealed an additional extra-
synaptic localization of these proteins in superresolution (STED) im-
aging due to their ability to more easily penetrate samples (Maidorn 
et al., 2019).
Affimers, like antibodies and nanobodies, may well be able to 
recognize specific posttranslational modifications and/or protein 
conformations. For example, of the four Affimers raised to F-actin, 
only one Affimer bound F-actin in paraformaldehyde-fixed cells (Af-
fimer 14; Lopata et al., 2018), whereas all four Affimers bound F-
actin in methanol-fixed cells. One potential explanation for this is 
that methanol fixation has a small effect on F-actin structure, which 
is enough to prevent the binding of phalloidin (Lopata et al., 2018; 
Mentes et al., 2018). It is possible that the three F-actin Affimers that 
only bind F-actin in methanol-fixed cells are also sensitive to this 
structural change. This suggests that further work and tailoring the 
screening process could enable the retrieval of Affimers that recog-
nize specific protein conformations. In a further example, we origi-
nally recovered 10 Affimers to tubulin, but only one of these recog-
nized and labeled microtubules in interphase cells (Tiede et al., 
2017). However, the Affimers were raised against tubulin purified 
from brain, which contains multiple tubulin isoforms and multiple 
posttranslational modifications. Therefore, it is possible that some 
of these Affimers may recognize specific tubulin isoforms or post-
translational modifications that are not commonly present in cul-
tured cells but are present in the brain. Work is currently underway 
to explore this possibility.
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Overall, this is an exciting time for imaging. Technology is driving 
forward the development of sophisticated imaging techniques that 
are revealing more detail about protein organization in cells than 
ever before. The development of nanobodies and small non-anti-
body binding proteins such as Affimers are allowing us to capitalize 
on the potential of superresolution imaging by providing probes 
with very small linkage errors. Together, these approaches provide 
us with much better certainty as to the location of our favorite pro-
teins of interest.
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